The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
about
Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indicationsRepurposing metformin: an old drug with new tricks in its binding pocketsBeneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metforminDiabetes mellitus and metformin in hepatocellular carcinomaTargeting mTOR in Pancreatic Ductal AdenocarcinomaMetformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-AnalysisEnergy disruptors: rising stars in anticancer therapy?Obesity and cancer: mechanistic insights from transdisciplinary studiesAdaptive responses of androgen receptor signaling in castration-resistant prostate cancerTreatment Strategies that Enhance the Efficacy and Selectivity of Mitochondria-Targeted Anticancer AgentsMechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cellsMetformin and the risk of cancer: time-related biases in observational studiesCellular and molecular mechanisms of metformin: an overviewNew promises for metformin: advances in the understanding of its mechanisms of actionChemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancerBreast cancer chemoprevention: old and new approachesPPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic DrugsMetformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: A meta-analysisAnti-tumor activity of metformin: from metabolic and epigenetic perspectivesPharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 StudiesMetformin as a new anti-cancer drug in adrenocortical carcinomaAcadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell deathIdentification of an annonaceous acetogenin mimetic, AA005, as an AMPK activator and autophagy inducer in colon cancer cellsAMPK activators suppress cervical cancer cell growth through inhibition of DVL3 mediated Wnt/β-catenin signaling activityMetformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cellsResponse of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combinedEffect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studiesPreoperative glycemic control status as a significant predictor of biochemical recurrence in prostate cancer patients after radical prostatectomyMetformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer CellsAssociation between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort StudyMetformin Induces Cell Cycle Arrest, Reduced Proliferation, Wound Healing Impairment In Vivo and Is Associated to Clinical Outcomes in Diabetic Foot Ulcer PatientsMetformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived XenograftsAssessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS)Metformin effects on biochemical recurrence and metabolic signaling in the prostate.Use of Fluorescence Lifetime Imaging Microscopy (FLIM) as a Timer of Cell Cycle S PhaseEfficacy of metformin for advanced-stage endometrial cancer: A case reportMetformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16Minireview: Obesity and breast cancer: a tale of inflammation and dysregulated metabolismMetformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis.Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.
P2860
Q22242884-7A522A07-FD59-433A-BD3F-8105A0753CF8Q22250976-924194C3-A658-404B-894F-1A5CFB675746Q24642412-4C672123-DDD9-4641-B9D8-23197828A326Q26741205-065488B8-AB9F-4C4B-91D7-4FCFED78C980Q26747291-FEC7EF86-96C0-49E4-AEE6-4799DA686C4AQ26765139-03D292ED-6E3C-4D87-BCBA-E593E5E92F74Q26771300-17BF3CC2-5DFD-4BA9-8858-7D6BEE7473C5Q26786829-9B1CDB57-2EF9-4468-8470-E586AE0BA6DBQ26795625-56417775-2171-4224-96B8-0DC129F67B2EQ26800890-4A5A1472-2B53-4818-AF66-8E211CE72BEDQ26827387-5F37DCE3-CCCA-464D-BC35-A5FE15B95AFFQ26999266-C546A09F-2CA4-4967-B5F0-1A383E27AC81Q27013561-B86486CD-5736-4894-97B7-D5E02674ECD1Q27023545-521D7963-B0C1-4AB8-B3D3-4B46E1E82991Q27026428-D08ED13D-9527-40FE-9FB8-657C54A95E86Q27693259-ED29CBFC-11AC-4C1A-B455-DEDA4D0C4035Q28066756-0069189F-D032-41AA-99B6-5E0B09983F96Q28072501-8FD32316-3A67-495D-B7D1-2110FE63616EQ28080170-23C7AB14-40D7-4D36-A6D4-48EDD3F4F15BQ28084927-F43865D3-ED49-4B08-9BD5-E0474B6D1F7FQ28468634-E77D17EB-6B7F-4CA3-A674-D4E17DBDDB06Q28471941-C120F780-23A6-4CE3-A621-1BF75C56F4BEQ28484273-BD0B9729-A8EE-4918-A509-569E6A2232F8Q28484795-7CF44715-4968-4FBB-9E2A-690ACCF4F5FAQ28539104-7235C23E-AB55-4A28-A42E-9117FB581FD8Q28539523-7F6D302C-5171-43FC-B8FD-E592DF303F28Q28542914-C2D2F080-340B-4D9C-A14C-41637F6FECBCQ28546623-19849EDE-2BD2-42F0-B246-30944702ADBDQ28547140-34937608-72A8-4BB2-8488-8198224F6146Q28547270-4D63D099-78DC-4E79-B2D3-191BB3D06698Q28550674-DBF10A90-8699-4045-B44C-69F1F5C8E023Q28552408-03F50D71-3503-4A37-959A-EF000345ADFEQ30000285-996D5BE2-AD0C-4977-9E44-77D937C6C2FAQ30665188-4CD0AADA-E0F8-4E00-A4B2-85AD7148EA77Q32184002-65B7B6EC-1ACF-4082-A87B-5BE8BEA38CEAQ33598291-12AC37F4-BC1B-408B-8E54-85386BDFB8C1Q33602223-352DA099-7715-4358-9052-315243FE582FQ33635798-941ECB95-AB4E-45B9-99E4-7BC5245744AFQ33648824-AC6DC394-C25A-4D0D-9AA4-FEE7269A8635Q33668168-3B7EB82A-33B2-45DF-B835-AC8B4FA7070B
P2860
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The antidiabetic drug metformi ...... a decrease of cyclin D1 level.
@en
type
label
The antidiabetic drug metformi ...... a decrease of cyclin D1 level.
@en
prefLabel
The antidiabetic drug metformi ...... a decrease of cyclin D1 level.
@en
P2093
P2860
P50
P356
P1433
P1476
The antidiabetic drug metformi ...... a decrease of cyclin D1 level
@en
P2093
I Ben Sahra
P Colosetti
Y Le Marchand-Brustel
P2860
P2888
P304
P356
10.1038/SJ.ONC.1211024
P407
P577
2008-01-21T00:00:00Z
P5875
P6179
1036402265